“NCI OA Special Notice of Subcontract Opportunity at the Frederick National Laboratory for Cancer Research”

This Special Notice is not a formal Invitation for Bid (IFB), Request for Proposal (RFP), Request for Quotation (RFQ) nor any type of Solicitation for offers. In accordance with FAR 15.201(d), this Special Notice is intended FOR INFORMATIONAL PURPOSES ONLY in order to publicize the requirements of the Frederick National Laboratory for Cancer Research (FNLCR).

The FNLCR is a Government-Owned Contractor-Operated Federally Funded Research and Development Center (FFRDC) located at Fort Detrick, Maryland. The FNLCR partners with university, Government, and corporate scientists to speed the translation of laboratory research into new diagnostic tests and treatments for cancer and AIDS. FNLCR is a multi-program laboratory currently operated by Leidos Biomedical Research, Inc. (Leidos Biomed) for the National Cancer Institute (NCI) under Prime Contract No. 75N91019D00024 & HHSN261201500003I, which provides Operations and Technical Support (OTS) for the FNLCR.

The Government assumes no liability for reimbursement for any effort or associated costs to respond, nor for any information provided as a result of this Special Notice as no information is being requested. Please be advised that any submissions provided, despite that no information is requested, become Government property and will not be returned, nor will there be any ensuing discussions or debriefings.

Responses submitted to this Special Notice are not offers and cannot be accepted by the U.S. Government to form a binding contract. It is the responsibility of the interested parties to monitor this site and any sites referenced herein for additional information pertaining to business opportunities with the FNLCR, if any.

The scope of this effort encompasses the evaluation, selection, configuration, and initial implementation of a Laboratory Information Management System (LIMS) to support the NIH Standardized Organoid Modeling (SOM) Initiative. The selected subcontractor will deliver a scalable, extensible platform capable of supporting integrated laboratory workflows, including protocol development, assay management, automation integration, and AI/ML-enabled analytics. This includes system architecture design, configuration of core data models, integration with laboratory instrumentation, and implementation of secure, compliant data management practices aligned with federal standards.

The LIMS must support key SOM functional priorities, including standardized protocol execution, high-throughput experimental workflows, and comprehensive biological sample tracking with associated metadata. The system must also enable efficient, programmatic access to data through well-defined APIs and standardized formats, allowing seamless extraction and integration into downstream AI/ML pipelines. This capability is critical to support SOM’s AI/ML-driven optimization and decision support functions, ensuring that experimental data can be readily ingested with minimal transformation and latency. The subcontractor will collaborate with NIH stakeholders to ensure interoperability with related systems and alignment with the broader SOM framework, with initial implementation focused on core capabilities and future scalability.

Leidos Biomedical Research, Inc. Point of Contact for a copy of Solicitation/RFP No: S26-123:

Josh Wynne, Subcontracts Manager at josh.wynne@nih.gov

For information concerning other opportunities with the FNLCR, please refer to:

https://frederick.cancer.gov/workwithus/solicitations